Literature DB >> 18322020

LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes.

Katherine J Kelly1, Pengfei Wu, Carolyn E Patterson, Constance Temm, Jesus H Dominguez.   

Abstract

The early nephropathy in obese, diabetic, dyslipidemic (ZS) rats is characterized by tubular lipid accumulation and pervasive inflammation, two critically interrelated events. We now tested the hypothesis that proximal tubules from ZS obese diabetic rats in vivo, and proximal tubule cells (NRK52E) exposed to oxidized LDL (oxLDL) in vitro, change their normally quiescent epithelial phenotype into a proinflammatory phenotype. Urine of obese diabetic rats contained more lipid peroxides, and LOX-1, a membrane receptor that internalizes oxidized lipids, was mobilized to luminal sites. Levels of ICAM-1 and focal adhesion kinase, which participate in leukocyte migration and epithelial dedifferentiation, respectively, were also upregulated in tubules. NRK52E cells exposed to oxLDL showed similar modifications, plus suppression of anti-inflammatory transcription factor peroxisome proliferator-activated receptor-delta. In addition, oxLDL impaired epithelial barrier function. These alterations were prevented by an anti-LOX-1 antibody. The data support the concept that tubular LOX-1 activation driven by lipid oxidants in the preurine fluid is critical in the inflammatory changes. We suggest that luminal lipid oxidants and abnormal tubular permeability may be partly responsible for the renal tubulointerstitial injury of obesity, diabetes, and dyslipidemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322020     DOI: 10.1152/ajprenal.00396.2007

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  23 in total

1.  Progressive renal vascular proliferation and injury in obese Zucker rats.

Authors:  Radu Iliescu; Alejandro R Chade
Journal:  Microcirculation       Date:  2010-05       Impact factor: 2.628

Review 2.  Nuclear receptors in renal disease.

Authors:  Moshe Levi
Journal:  Biochim Biophys Acta       Date:  2011-04-14

Review 3.  Nuclear hormone receptors in diabetic nephropathy.

Authors:  Xiaoxin X Wang; Tao Jiang; Moshe Levi
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

Review 4.  Hyperlipidemia: a new therapeutic target for diabetic neuropathy.

Authors:  Andrea M Vincent; Lucy M Hinder; Rodica Pop-Busui; Eva L Feldman
Journal:  J Peripher Nerv Syst       Date:  2009-12       Impact factor: 3.494

5.  Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Oguzhan Ozturk; Yasar Colak; Ebubekir Senates; Yusuf Yilmaz; Celal Ulasoglu; Levent Doganay; Seyma Ozkanli; Yasemin Musteri Oltulu; Ender Coskunpinar; Ilyas Tuncer
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

6.  Role of triglyceride-rich lipoproteins in renal injury.

Authors:  Kit Fai Ng; Hnin Hnin Aung; John C Rutledge
Journal:  Contrib Nephrol       Date:  2011-06-09       Impact factor: 1.580

7.  High-calorie diet partially ameliorates dysregulation of intrarenal lipid metabolism in remnant kidney.

Authors:  Hyun Ju Kim; Jun Yuan; Keith Norris; Nosratola D Vaziri
Journal:  J Nutr Biochem       Date:  2009-12-01       Impact factor: 6.048

Review 8.  Innate immune activation in obesity.

Authors:  Carey N Lumeng
Journal:  Mol Aspects Med       Date:  2012-10-13

9.  Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1.

Authors:  Andrea M Vincent; John M Hayes; Lisa L McLean; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Eva L Feldman
Journal:  Diabetes       Date:  2009-07-10       Impact factor: 9.461

10.  Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Yupanqui Caldas; Shinobu Miyazaki-Anzai; Hannah Santamaria; Cydney Urbanek; Nathaniel Solis; Pnina Scherzer; Linda Lewis; Frank J Gonzalez; Luciano Adorini; Mark Pruzanski; Jeffrey B Kopp; Jill W Verlander; Moshe Levi
Journal:  Diabetes       Date:  2010-08-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.